Publication:


abstract

We report a case of rectal cancer resulting in a Pathologically complete response of the primary tumor by systemic chemotherapy with panitumumab, a new endothelial growth factor receptor(EGFR)antibody. A 56-year-old man was diagnosed as having unresectable stage IV rectal cancer with local invasion and lung metastasis, and underwent systemic chemotherapy by FOLFOX, combined with panitumumab as a first-line therapy. After 3 courses of FOLFOX and 3 courses of FOLFOX with panitumumab, the treatment regimen was changed to FOLFIRI with panitumumab to prevent peripheral neuropathy. After 5 courses of FOLFIRI with panitumumab, pelvic computed tomography(CT)revealed that the primary tumor was markedly reduced, and the intrapelvic direct invasion was resolved. On the post-treatment chest CT, lung metastasis had disappeared. A low anterior resection preserving the automatic nerves, the colonic J-pouch and anal anastomosis, was performed 20 days after the last chemotherapy. Although the whole tumor-like lesion of the specimen was sectioned macroscopically at 5-mm intervals, no vivid tumor cells were detected at the pathological examination. The patient's postoperative course was uneventful, and no recurrence occurred 5 months after the operation. The EGFR receptor antibody is reported to have a significant anti-cancer effect for colorectal cancer without the KRAS gene mutation. In cases with relatively large tumors especially, EGFR antibody can be an effective first-line treatment.

Related Articles
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Cancer Treat Rev. 2010
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y. Cancer Treat Rev. 2010 Feb; 36 Suppl 1:S11-4.
[A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX].
Gan To Kagaku Ryoho. 2011
[A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX].
Yamazoe S, Yamaguchi K, Terasawa H, Ojima T, Tsujimura H, Shimomura T. Gan To Kagaku Ryoho. 2011 Jan; 38(1):125-8.
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Magy Onkol. 2010
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L. Magy Onkol. 2010 Dec; 54(4):383-94.
Review Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Clin Ther. 2010
Review Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J, Punt CJ. Clin Ther. 2010 Mar; 32(3):437-53.
Review [A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer].
Gan To Kagaku Ryoho. 2011
Review [A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer].
Hasegawa H, Ninomiya M, Honbou T, Hamatsu T, Kudo K, Ushijima C, Kabashima A, Kitamura M. Gan To Kagaku Ryoho. 2011 Nov; 38(12):2310-2.